Dr. Don is an interventional cardiologist and a UW Assistant Professor of Medicine in the Division of Cardiology. He is experienced with percutaneous treatment for valvular heart disease, particularly transcatheter aortic valve replacement (TAVR), mitral balloon valvuloplasty, and transcatheter pulmonic valve replacement. He specializes in structural and congenital heart disease including catheter based treatment of atrial and ventricular septal defects. patent ductus arteriosus (PDA), paravaluvlar leaks, and coronary fistulae. He is also experienced in the management of acute coronary syndromes (heart attacks), percutaneous coronary interventions (coronary angioplasty and stenting), and chronic angina.
Patient Care Philosophy
The best healthcare involves a close collaboration between the physician and patient. I see my role as helping to educate patients about cardiovascular disease and the different therapies available, partnering with them to be active decision makers in their care.
I want to bring the most advanced technologies, therapies and data to the table when considering treatment for my patients, knowing that sometimes the best medicine may simply be doing things such as improving diet, exercise and focusing on their quality of life.
Dr. Don is an investigator in the PARTNER II study of the Edwards Sapien percutaneous aortic valve, which is a minimally invasive treatment for patients with aortic valve stenosis who are intermediate risk for traditional valve surgery. He is also an investigator for the RENEW study, of using autologous CD34+ cells to treat chronic refractory angina in patients without revascularization options. In addition, he is a national consultant for the AIM-HIGH study of the cardioprotective effects of the HDL raising drug niacin.
His current NIH-funded research investigates the use of cell and biologic therapies for the treatment of severe atherosclerotic coronary artery disease not amenable to traditional revascularization.
He was a regional coordinator for the OASIS-7 CURRENT study of clopidogrel dosing in patients with non-ST-elevation myocardial infarction, and is involved in evaluating hospital registries designed to improve quality of care for patients undergoing percutaneous coronary interventions.
|Massachusetts General Hospital Program||Fellowship|
|Univ. of Calif. San Francisco||Medical education||2001|
|Univ. of Chicago Hospitals||Internship|
|Univ. of Chicago Hospitals||Residency|
|UW - Division of Cardiology||Fellowship|
|Univ. of Washington||Master Public Health||2008|
|MD||Univ. of Calif. San Francisco||2001|
|American Board of Internal Medicine||Cardiovascular Disease||2007|
|American Board of Internal Medicine||Internal Medicine||2004|
|American Board of Internal Medicine||Interventional Cardiology||2009|